Plain-English translation of NCT05347069 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether , a common blood-thinning medication, can help prevent heart attacks and related complications in people who have chronic heart disease but are not eligible for surgery to fix their blocked arteries. Right now, doctors don't know if the medication helps this specific group of patients. The study will compare people who take the medication daily against those who don't, to see which approach is safer and more effective.
is already known to be helpful for people recovering from a heart attack or those who have had heart surgery, but there's been no clear evidence about whether this medication actually helps people with ongoing heart disease who cannot have surgery. This trial exists to fill that knowledge gap and help doctors make better treatment decisions for this group.
You likely qualify if…
You likely don't qualify if…
If you join, you will be randomly assigned to either take a daily tablet (100 mg) or not take . The study is open-label, meaning you and your doctors will know which group you're in. You'll need to visit the research clinic for check-ups and monitoring over time to see how you're doing and whether you experience any heart problems or side effects. The study involves about 2,890 participants across multiple medical centers.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
Japan
Phase
Post-approval monitoring
Sponsor
Takeshi Morimoto
Enrollment target
~2,890 participants
Started
June 2022
Primary completion
March 2030
Age range
20 Years and older
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Takeshi Kimura, MD, PhD
Kyoto University, Graduate School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.